AbbVie strikes $10.9 billion deal for Apogee Therapeutics
Yesterday 12:02
AbbVie strikes $10.9 billion deal for Apogee Therapeutics June 22 (Reuters) - AbbVie ABBV.N will acquire biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, they said on Monday, as the company builds its next-generation immunology pipeline.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sriraj Kalluvila)
Recent news on GSK
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)
Brief: GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA